PTC Therapeutics Inc. (PTCT) and Jounce Therapeutics Inc. (NASDAQ:JNCE) Comparing side by side – FinanceMercury

PTC Therapeutics Inc. (NASDAQ:PTCT) and Jounce Therapeutics Inc. (NASDAQ:JNCE), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation of the two firms.

Valuation & Earnings

Table 1 highlights PTC Therapeutics Inc. and Jounce Therapeutics Inc.s gross revenue, earnings per share and valuation.

Profitability

Table 2 shows the return on equity, return on assets and net margins of the two firms.

Liquidity

PTC Therapeutics Inc.s Current Ratio is 3.3 while its Quick Ratio is 3.2. On the competitive side is, Jounce Therapeutics Inc. which has a 2.2 Current Ratio and a 2.2 Quick Ratio. PTC Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Jounce Therapeutics Inc.

Analyst Recommendations

Ratings and Recommendations for PTC Therapeutics Inc. and Jounce Therapeutics Inc. can be find in next table.

PTC Therapeutics Inc. has a 25.42% upside potential and an average price target of $50.67.

Institutional and Insider Ownership

Institutional investors owned 85.61% of PTC Therapeutics Inc. shares and 74.2% of Jounce Therapeutics Inc. shares. PTC Therapeutics Inc.s share owned by insiders are 0.3%. Competitively, Jounce Therapeutics Inc. has 0.7% of its share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year PTC Therapeutics Inc.s stock price has smaller growth than Jounce Therapeutics Inc.

Summary

Jounce Therapeutics Inc. beats PTC Therapeutics Inc. on 6 of the 11 factors.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companys lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy. In addition, the companys product candidate in cancer stem cell program include PTC596, an orally bioavailable and potent small molecule, which has completed phase I clinical trials that targets tumor stem cell populations by reducing the activity and amount of a protein called BMI1. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. Its lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. The company is also developing JTX-4014, an anti-PD-1 antibody. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

View post:
PTC Therapeutics Inc. (PTCT) and Jounce Therapeutics Inc. (NASDAQ:JNCE) Comparing side by side - FinanceMercury